# The Cross-Knit Between Immune Cells and Thyroid Function in Autoimmune Thyroid Disorders: What We Can Learn from Inborn Errors of Immunity

**Authors:** Laura Grilli, Francesca Cillo, Roberta Romano, Giuliana Giardino, Francesca Romana Rotondo, Sara Vasaturo, Mariacarolina Salerno, Donatella Capalbo

PMC · DOI: 10.3390/children13020169 · 2026-01-25

## TL;DR

This paper explores how immune system defects in rare genetic disorders can help us understand the causes of autoimmune thyroid diseases.

## Contribution

The paper proposes that inborn errors of immunity serve as a model to study immune tolerance breakdown in autoimmune thyroid diseases.

## Key findings

- Autoimmune thyroid diseases share pathogenetic mechanisms with inborn errors of immunity.
- Genetic and epigenetic changes in immune tolerance contribute to thyroid autoimmunity.
- Immune defects in rare disorders can reveal molecular pathways driving autoimmune thyroid diseases.

## Abstract

What are the main findings?
Autoimmune thyroid diseases (AITDs) share key pathogenetic mechanisms with inborn errors of immunity (IEIs), making IEIs a natural model to study immune tolerance breakdown.Genetic and epigenetic perturbations affecting central and peripheral tolerance mechanisms contribute to the development of thyroid autoimmunity.

Autoimmune thyroid diseases (AITDs) share key pathogenetic mechanisms with inborn errors of immunity (IEIs), making IEIs a natural model to study immune tolerance breakdown.

Genetic and epigenetic perturbations affecting central and peripheral tolerance mechanisms contribute to the development of thyroid autoimmunity.

What is the implication of the main findings?
Understanding how specific immune defects lead to AITDs enables the identification of precise molecular pathways driving thyroid autoimmunity.These insights support the development of targeted, pathway-specific therapies and precision-medicine approaches for AITDs.

Understanding how specific immune defects lead to AITDs enables the identification of precise molecular pathways driving thyroid autoimmunity.

These insights support the development of targeted, pathway-specific therapies and precision-medicine approaches for AITDs.

Autoimmune thyroid diseases (AITDs), including Hashimoto thyroiditis and Graves’ disease, are the most common autoimmune endocrinopathies, affecting up to 5% of the population. Pathogenetic pathways have not yet been fully elucidated, even though different immune-genetic alterations have been proposed. Specific immune defects presenting with AITDs may serve as an experimentum naturae to study the involvement of a specific pathway in the pathogenesis of the disease. In fact, since immune dysregulation with autoimmunity frequently characterize inborn errors of immunity (IEIs), understanding the mechanisms of immune tolerance breakdown leading to autoimmunity in these conditions may provide useful insight to understand the pathogenesis of AITDs. In this review, we will highlight the main immunological aspects of AITDs and their pathogenesis in IEIs.

## Linked entities

- **Diseases:** Hashimoto thyroiditis (MONDO:0007699), Graves’ disease (MONDO:0005364), inborn errors of immunity (MONDO:0003778)

## Full-text entities

- **Genes:** CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NKRF (NFKB repressing factor) [NCBI Gene 55922] {aka ITBA4, NRF, XTBD3}, RPL17 (ribosomal protein L17) [NCBI Gene 6139] {aka DBA22, L17, PD-1, RPL23, uL22}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, MIR142 (microRNA 142) [NCBI Gene 406934] {aka MIRN142, mir-142}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, JAK3 (Janus kinase 3) [NCBI Gene 3718] {aka JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, TG (thyroglobulin) [NCBI Gene 7038] {aka AITD3, TGN}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TNFRSF13C (TNF receptor superfamily member 13C) [NCBI Gene 115650] {aka BAFF-R, BAFFR, BROMIX, CD268, CVID4, prolixin}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MIR301A (microRNA 301a) [NCBI Gene 407027] {aka MIR301, MIRN301, MIRN301A, mir-301a}, TNFRSF13B (TNF receptor superfamily member 13B) [NCBI Gene 23495] {aka CD267, CVID, CVID2, IGAD2, RYZN, TACI}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, AIRE (autoimmune regulator) [NCBI Gene 326] {aka AIRE1, APECED, APS1, APSI, PGA1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}
- **Diseases:** X-linked) syndrome (MESH:C564469), viral and fungal infections (MESH:D014777), hypopituitarism (MESH:D007018), cytopenia (MESH:D006402), eczematous dermatitis (MESH:D004485), dental and nail dystrophy (MESH:D009260), hypothyroidism (MESH:D007037), immunodeficiency (MESH:D007153), rheumatoid arthritis (MESH:D001172), CTLA-4 deficiency (MESH:C535887), skin super-infections (MESH:C535318), weight loss (MESH:D015431), airways and gastrointestinal infections (MESH:D005767), Inborn Errors of Immunity (MESH:D007154), COVID-19 (MESH:D000086382), infection (MESH:D007239), autoimmune endocrinopathies (MESH:C567425), T1D (MESH:D003922), diffuse (MESH:D008228), palpitations (MESH:D006331), SIgAD (MESH:C536290), Candidiasis (MESH:D002177), organ specific diseases (MESH:D000092124), Ectodermal:Distrophy (MESH:D004476), AITDs (MESH:D013967), Thyroid dysfunction (MESH:D013959), bacterial (MESH:D001424), IPEX (MESH:C580192), infectious diseases (MESH:D003141), goiter (MESH:D006042), X-Linked (MESH:C536424), vascular anomalies (MESH:D020785), tract (MESH:D014570), autoimmune clinical conditions (MESH:D013568), viral, bacterial and fungal infectious diseases (MESH:D018792), Immune Dysregulation (OMIM:614878), skin diseases (MESH:D012871), CVID (MESH:D017074), IgA deficient (MESH:D017098), injury to (MESH:D014947), gastrointestinal and rheumatological symptoms (MESH:D012817), chronic inflammation (MESH:D007249), mycobacterial, (MESH:C564468), DM1 (MESH:D009223), CMC (MESH:D002178), atrophy (MESH:D001284), autosomal dominant IEI (MESH:C566739), ALPS (MESH:D056735), malignancies (MESH:D009369), adrenal failure (MESH:D051437), Graves' orbitopathy (MESH:D049970), diarrhea (MESH:D003967), hyperthyroidism (MESH:D006980), fatigue (MESH:D005221), autoimmune manifestation (MESH:D012877), atopy (MESH:C564133), AIRE deficiency (MESH:D001327), hypogammaglobulinemia (MESH:D000361), sinopulmonary infections (MESH:C536718), GOF (MESH:D015430)
- **Chemicals:** phthalates (MESH:C032279), TG (MESH:D013866), PFAS (-), T4 (MESH:D013974), bisphenols (MESH:C543008), hydrogen peroxide (MESH:D006861), radioiodine (MESH:C000614965), Rituximab (MESH:D000069283), iodine (MESH:D007455), reactive oxygen species (MESH:D017382), Baricitinib (MESH:C000596027), Tocilizumab (MESH:C502936), Tofacitinib (MESH:C479163), per- and polyfluoroalkyl substances (MESH:D005466), Adalimumab (MESH:D000068879), Infliximab (MESH:D000069285), Ruxolitinib (MESH:C540383), methimazole (MESH:D008713)
- **Species:** Homo sapiens (human, species) [taxon 9606], Giardia duodenalis (species) [taxon 5741], Helicobacter pylori (species) [taxon 210], Borreliella burgdorferi (Lyme disease spirochete, species) [taxon 139], Mus musculus (house mouse, species) [taxon 10090], Yersinia enterocolitica (species) [taxon 630], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]
- **Mutations:** -670 A/G, -1377 G/A

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12939510/full.md

---
Source: https://tomesphere.com/paper/PMC12939510